Belantamab Mafodotin Combination Therapy
A Phase I/II Study of the Safety, Tolerability and Efficacy of Belantamab Mafodotin (GSK2857916) in Combination With Iberdomide (CC-220)/Dexamethasone Versus Belantamab Mafodotin (GSK2857916)/Dexamethasone in Relapsed Refractory Multiple Myeloma
More Information
- Trial Status
- Not yet accepting
- Trial Phase
- Phase 1/2
- Enrollment
- 88 patients (estimated)
- Sponsors
- Alliance for Clinical Trials in Oncology
- Collaborators
- National Cancer Institute (NCI)
- Tags
- Antibody Drug Conjugate (ADC), B-Cell Maturation Antigen (BCMA), Randomization
- Trial Type
- Treatment
- Last Update
- 1 day ago
- SparkCures ID
- 2040
- NCT Identifier
- NCT06232044
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.